DALLAS, Nov. 2, 2016 /PRNewswire/ -- A new hair loss prevention and reversal line launching in December 2016 is poised to disrupt the $3.5 billion hair loss market in the US where over 80 million people suffer from hair loss.
evolis ® is a hair care system, that is clinically proven to reduce hair loss, increase hair density, and increase the rate of hair growth. In addition to being the first clinically validated topical hair loss product to be introduced in over 30 years, evolis ® is the first product to tackle the problem at the root of its cause - by inhibiting the FGF5 protein, a crucial negative regulator of hair growth. The fgf5 gene, responsible for the production of the FGF5 protein, was discovered in 1994 by scientists at the University of California, San Francisco. They observed that in the absence of FGF5, unusually long hair was evident. evolis ® is formulated from FGF5 blocking natural plant extracts that have been screened using a number of specialized tests developed by eminent evolis ® scientist, Dr. Masakuni Yamamoto. Dr. Yamamoto researched hair biology for over 20 years and is responsible for identifying the key botanical ingredients in the highly potent evolis ® formulation.